search
Back to results

Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer (CoME-In)

Primary Purpose

Colon Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Conventional Right hemicolectomy (Non-CME)
Right hemicolectomy with CME+CVL
Sponsored by
University of Turin, Italy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colon Cancer focused on measuring colon cancer, Right colon cancer, Complete mesocolic excision, CME, Right Hemicolectomy, Right Colectomy

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • American Society of Anesthesiologists(ASA) grade I-III.
  • Right colon cancer (*The right-sided location of the cancer is defined as the location from the caecum up to the proximal third of the transverse colon), preoperative assessment of tumor stage T2-T4a, any N or T any N+ according to the National Comprehensive Cancer Network(NCCN) clinical practice guidelines in oncology: colon cancer version 2.2015); no distant metastasis.
  • Informed consent

Exclusion Criteria:

  • Age > 85 years old.
  • T1, N0
  • T4b, any N
  • BMI > 30.
  • Metastatic disease (Abdominal and chest CT scan will be mandatory to exclude distant metastasis.)
  • American Society of Anesthesiologists(ASA) grade IV.
  • History of cancer in recent 5 years.
  • Need for Emergency surgery.
  • Infectious disease requiring treatment.
  • Pregnancy.
  • Use of systemic steroids.
  • No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease.

Sites / Locations

  • Ospedale della Misericordia
  • Ospedale Città di Sesto San Giovanni
  • S. Andrea Hospital
  • Candiolo Cancer Institute - IRCCS
  • Ospedale E. Agnelli Pinerolo
  • Maggiore Bellaria Hospital, Bologna
  • Università degli Studi di Ferrara
  • Ospedale Policlinico San Martino
  • Azienda Ospedaliera Universitaria Policlinico "G. Martino"
  • European Institute of Oncology
  • Federico II University
  • University of Rome Tor Vergata
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  • University of Turin (AOU.San Luigi Gonzaga)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Conventional Right hemicolectomy (Non-CME)

Right hemicolectomy with CME+CVL

Arm Description

Patients will undergo conventional non-CME procedure.

Patients will undergo Right hemicolectomy CME+CVL procedure.

Outcomes

Primary Outcome Measures

Disease-free survival at 3 years
The length of time after surgery without any signs or symptoms of local or distant recurrence.

Secondary Outcome Measures

Safety-Operative time.
Total time from incision to skin closure expressed in minutes.
Safety-Intraoperative blood loss.
Defined by the volume drained in cm2 into aspiration systems and weight of gauzes, calculated, subtracting the weight of the dry gauzes and volume of saline solution used for irrigation.
Safety-Intraoperative blood transfusion.
Defined as the number of red blood cells, platelets, or plasma units transfused during the intraoperative time.
Safety- Intraoperative Complications.
Defined as any deviation from the ideal intraoperative course occurring during the operative time, Using the Classification of Intraoperative Complications(CLASSIC).
Early postoperative complications.
Number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.
Late postoperative complications.
The number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.
Safety- Length of stay.
Defined as the length of an inpatient episode of care, calculated from the day of operation to the first discharge and based on the number of nights spent in the hospital.
Safety- Postoperative mortality rate.
The all-cause death rate, within 30 days after surgery in or out of the hospital.
Overall Survival at 3 years
Defined as the time from random assignment to the date of death due to any cause.
Overall Survival at 5 years.
Defined as the time from random assignment to the date of death due to any cause.
Disease-free survival.
Defined as the length of time after Surgical treatment (CME+CVL or Conventional non-CME procedure) that the patient survives without any signs or symptoms of colon cancer.
Other Oncologic outcomes.
The number of positive, negative, and total lymph nodes harvested, Quality of surgery specimen, quality of life by EORTC specific Questionnaires

Full Information

First Posted
April 23, 2021
Last Updated
November 11, 2022
Sponsor
University of Turin, Italy
Collaborators
Federico II University, Agnelli Hospital, Italy, Ospedale della Misericordia, Candiolo Cancer Institute - IRCCS, Maggiore Bellaria Hospital, Bologna, Università degli Studi di Ferrara, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Ospedale Policlinico San Martino, University of Rome Tor Vergata, S. Andrea Hospital, European Institute of Oncology
search

1. Study Identification

Unique Protocol Identification Number
NCT04871399
Brief Title
Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer
Acronym
CoME-In
Official Title
Complete Mesocolic Excision With Central Vascular Ligation in Comparison With Conventional Surgery for the Right Colon Cancer: An Italian Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 13, 2020 (Actual)
Primary Completion Date
January 1, 2027 (Anticipated)
Study Completion Date
January 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Turin, Italy
Collaborators
Federico II University, Agnelli Hospital, Italy, Ospedale della Misericordia, Candiolo Cancer Institute - IRCCS, Maggiore Bellaria Hospital, Bologna, Università degli Studi di Ferrara, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Ospedale Policlinico San Martino, University of Rome Tor Vergata, S. Andrea Hospital, European Institute of Oncology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An Italian randomized controlled trial parallel-group in patients with a malignant tumor of the right or proximal transverse colon requiring right hemicolectomy.
Detailed Description
This study aims to compare the Complete Mesocolic Excision With Central Vascular Ligation (CME+CVL) with the standard (non-CME) right hemicolectomy in patients with right or proximal transverse colon cancer stage II-IV(AJCC 8th edition) to determine the short and long term outcomes in terms of disease-free survival (DFS) as a primary endpoint, and safety, oncologic outcomes, quality of surgery and quality of life (QoL) as secondary endpoints. Eligible patients will be randomized with a 1:1 ratio between CME + CVL vs standard non-CME right colectomy. The randomization sequence will be generated centrally by a computed algorithm and kept concealed to investigators. The Right colectomy with CME + CVL includes the removal of the accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia. Despite the surgical approach and the type of procedure adopted, the operation should be strictly conducted following the general rules for colorectal oncologic resection, particularly as concerns proximal and distal margins length and lymph node retrieval. All surgical approaches (open, laparoscopic, or robotic) will be allowed while the type of anastomosis performed and drain placement will be up to the surgeon's discretion. Demographic, baseline, perioperative and postoperative characteristics will be analyzed as well. The study expected to last six and a half years, of which one and a half years for recruiting 416 patients, 208 each arm, with five years of follow-up. Patients will be followed up at 1, 4, 12, 24, 36, and 60 months postoperatively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colon Cancer
Keywords
colon cancer, Right colon cancer, Complete mesocolic excision, CME, Right Hemicolectomy, Right Colectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
416 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conventional Right hemicolectomy (Non-CME)
Arm Type
Active Comparator
Arm Description
Patients will undergo conventional non-CME procedure.
Arm Title
Right hemicolectomy with CME+CVL
Arm Type
Experimental
Arm Description
Patients will undergo Right hemicolectomy CME+CVL procedure.
Intervention Type
Procedure
Intervention Name(s)
Conventional Right hemicolectomy (Non-CME)
Intervention Description
Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
Intervention Type
Procedure
Intervention Name(s)
Right hemicolectomy with CME+CVL
Intervention Description
Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly: The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery. The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance.
Primary Outcome Measure Information:
Title
Disease-free survival at 3 years
Description
The length of time after surgery without any signs or symptoms of local or distant recurrence.
Time Frame
3 Years.
Secondary Outcome Measure Information:
Title
Safety-Operative time.
Description
Total time from incision to skin closure expressed in minutes.
Time Frame
Intraoperative
Title
Safety-Intraoperative blood loss.
Description
Defined by the volume drained in cm2 into aspiration systems and weight of gauzes, calculated, subtracting the weight of the dry gauzes and volume of saline solution used for irrigation.
Time Frame
Intraoperative
Title
Safety-Intraoperative blood transfusion.
Description
Defined as the number of red blood cells, platelets, or plasma units transfused during the intraoperative time.
Time Frame
Intraoperative
Title
Safety- Intraoperative Complications.
Description
Defined as any deviation from the ideal intraoperative course occurring during the operative time, Using the Classification of Intraoperative Complications(CLASSIC).
Time Frame
Intraoperative
Title
Early postoperative complications.
Description
Number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.
Time Frame
30 postoperative days.
Title
Late postoperative complications.
Description
The number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.
Time Frame
From the 31st postoperative days to the end of the study.
Title
Safety- Length of stay.
Description
Defined as the length of an inpatient episode of care, calculated from the day of operation to the first discharge and based on the number of nights spent in the hospital.
Time Frame
30 Days.
Title
Safety- Postoperative mortality rate.
Description
The all-cause death rate, within 30 days after surgery in or out of the hospital.
Time Frame
30 Days.
Title
Overall Survival at 3 years
Description
Defined as the time from random assignment to the date of death due to any cause.
Time Frame
3 Years.
Title
Overall Survival at 5 years.
Description
Defined as the time from random assignment to the date of death due to any cause.
Time Frame
5 Years.
Title
Disease-free survival.
Description
Defined as the length of time after Surgical treatment (CME+CVL or Conventional non-CME procedure) that the patient survives without any signs or symptoms of colon cancer.
Time Frame
5 Years.
Title
Other Oncologic outcomes.
Description
The number of positive, negative, and total lymph nodes harvested, Quality of surgery specimen, quality of life by EORTC specific Questionnaires
Time Frame
30 Days.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologists(ASA) grade I-III. Right colon cancer (*The right-sided location of the cancer is defined as the location from the caecum up to the proximal third of the transverse colon), preoperative assessment of tumor stage T2-T4a, any N or T any N+ according to the National Comprehensive Cancer Network(NCCN) clinical practice guidelines in oncology: colon cancer version 2.2015); no distant metastasis. Informed consent Exclusion Criteria: Age > 85 years old. T1, N0 T4b, any N BMI > 30. Metastatic disease (Abdominal and chest CT scan will be mandatory to exclude distant metastasis.) American Society of Anesthesiologists(ASA) grade IV. History of cancer in recent 5 years. Need for Emergency surgery. Infectious disease requiring treatment. Pregnancy. Use of systemic steroids. No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mario Solej, MD
Phone
00393388624939
Email
mariosolej@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hogla Aridai Resendiz Aguilar, MD
Phone
00393512338942
Email
hogla.resendizagu@edu.unito.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maurizio Degiuli, Professor
Organizational Affiliation
University of Turin, Department of Oncology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale della Misericordia
City
Grosseto
State/Province
Arezzo
ZIP/Postal Code
52100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paolo Pietro Bianchi, MD
Email
bianchippt@gmail.com
Facility Name
Ospedale Città di Sesto San Giovanni
City
Sesto San Giovanni
State/Province
Milano
ZIP/Postal Code
20099
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gianandrea Baldazzi., MD
Email
gbaldazzi@hotmail.com
First Name & Middle Initial & Last Name & Degree
Diletta CassiniI., MD
Email
diletta_cassini@yahoo.it
Facility Name
S. Andrea Hospital
City
La Spezia
State/Province
Spezia
ZIP/Postal Code
19121
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefano Berti, MD
Email
stefano.berti@asl5.liguria.it
First Name & Middle Initial & Last Name & Degree
Andrea Gennai, MD
Email
andrea.gennai@asl5.liguria.it
Facility Name
Candiolo Cancer Institute - IRCCS
City
Candiolo
State/Province
Torino
ZIP/Postal Code
10060
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe Spingolo, MD
Email
gspinoglio@icloud.com
First Name & Middle Initial & Last Name & Degree
Dario Ribero, MD
Email
dario.ribero@ircc.it
Facility Name
Ospedale E. Agnelli Pinerolo
City
Pinerolo
State/Province
Torino
ZIP/Postal Code
10064
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Muratore, MD
Email
amuratore@aslto3.piemonte.it
Facility Name
Maggiore Bellaria Hospital, Bologna
City
Bologna
ZIP/Postal Code
40124
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elio Jovine, MD
Email
elio.jovine@ausl.bologna.it
First Name & Middle Initial & Last Name & Degree
Raffaele Lombardi, MD
Email
elio.jovine@ausl.bologna.it
Facility Name
Università degli Studi di Ferrara
City
Ferrara
ZIP/Postal Code
44121
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gabriele Anania., MD
Email
g.anania@unife.it
Facility Name
Ospedale Policlinico San Martino
City
Genova
ZIP/Postal Code
16132
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefano Scabini, MD
Email
stefanoscabini@libero.it
Facility Name
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
City
Messina
ZIP/Postal Code
98124
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe Navarra, MD
Email
gnavarra@unime.it
Facility Name
European Institute of Oncology
City
Milano
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Romario Uberto Fumagalli, MD
Email
uberto.fumagalliromario@ieo.it
First Name & Middle Initial & Last Name & Degree
Laura Adamoli, MD
Email
laura.adamoli@ieo.it
Facility Name
Federico II University
City
Napoli
ZIP/Postal Code
80138
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Corcione, MD
Email
francesco.corcione@unina.it
First Name & Middle Initial & Last Name & Degree
Umberto Bracale, MD
Email
umbertobracale@gmail.com
Facility Name
University of Rome Tor Vergata
City
Rome
ZIP/Postal Code
00133
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe Sica, MD
Email
sigisica@gmail.com
Facility Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
City
Rome
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Domenico D'Ugo, MD
Email
biondi.alberto@gmail.com
First Name & Middle Initial & Last Name & Degree
Alberto Biondi, MD
Email
biondi.alberto@gmail.com
Facility Name
University of Turin (AOU.San Luigi Gonzaga)
City
Torino
ZIP/Postal Code
10043
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Solej, MD
Phone
00393388624939
Email
mario.solej@unito.it
First Name & Middle Initial & Last Name & Degree
Aridai Resendiz, MD
Phone
3512338942
Email
aridai.resendiz@icloud.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28157065
Citation
Bertelsen CA. Complete mesocolic excision an assessment of feasibility and outcome. Dan Med J. 2017 Feb;64(2):B5334.
Results Reference
background
PubMed Identifier
30207593
Citation
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum In: CA Cancer J Clin. 2020 Jul;70(4):313.
Results Reference
background
PubMed Identifier
30838463
Citation
Benz S, Tannapfel A, Tam Y, Grunenwald A, Vollmer S, Stricker I. Proposal of a new classification system for complete mesocolic excison in right-sided colon cancer. Tech Coloproctol. 2019 Mar;23(3):251-257. doi: 10.1007/s10151-019-01949-4. Epub 2019 Mar 5.
Results Reference
background
PubMed Identifier
16877723
Citation
Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006 Aug 1;24(22):3570-5. doi: 10.1200/JCO.2006.06.8866.
Results Reference
background
PubMed Identifier
23982425
Citation
Galizia G, Lieto E, De Vita F, Ferraraccio F, Zamboli A, Mabilia A, Auricchio A, Castellano P, Napolitano V, Orditura M. Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. Int J Colorectal Dis. 2014 Jan;29(1):89-97. doi: 10.1007/s00384-013-1766-x. Epub 2013 Aug 28.
Results Reference
background
PubMed Identifier
22473170
Citation
West NP, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, Sugihara K, Quirke P. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol. 2012 May 20;30(15):1763-9. doi: 10.1200/JCO.2011.38.3992. Epub 2012 Apr 2.
Results Reference
background
PubMed Identifier
20969719
Citation
Bertelsen CA, Bols B, Ingeholm P, Jansen JE, Neuenschwander AU, Vilandt J. Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision? Colorectal Dis. 2011 Oct;13(10):1123-9. doi: 10.1111/j.1463-1318.2010.02474.x.
Results Reference
background
PubMed Identifier
27566031
Citation
Kim NK, Kim YW, Han YD, Cho MS, Hur H, Min BS, Lee KY. Complete mesocolic excision and central vascular ligation for colon cancer: Principle, anatomy, surgical technique, and outcomes. Surg Oncol. 2016 Sep;25(3):252-62. doi: 10.1016/j.suronc.2016.05.009. Epub 2016 May 20.
Results Reference
background

Learn more about this trial

Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer

We'll reach out to this number within 24 hrs